Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

posted on Nov 22, 2018 01:11PM

JNJ got approval for Apalutamide in Feb 2018 for non - metastatic CRPC. Testing is still ongoing so they can get approval for mCRPC. They have been aware of this situation for a long time. I believe 3694 have already been tested in conjunction with Apalutamide however I can't find anything in print so take it for what it's worth. I believe I heard that at in a small group conversation at last years AGM. If anyone else that was present could chime in it would be appreciated.